ACT Capital Partners, L.P.’s Candel Therapeutics CADL Stock Holding History

ACT Capital Partners, L.P.’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.57M	Buy	+150,500	New	+$1.67M	1.02%	24

Other funds holding CADL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Torrey Growth & Income Advisors Del Mar, California $297M AUM 36.15% 1-Year Est. Return

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

ACT Capital Partners, L.P.'s CADL Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Candel Therapeutics (CADL) in Q3 2026: 150,500 shares worth $1.57M. The stake represents 1.02% of the portfolio and ranks #24 among its holdings.

46 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

ACT Capital Partners, L.P. held 150,500 shares of Candel Therapeutics worth $1.57M as of Q3 2026.
Candel Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
Candel Therapeutics made up 1.02% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #24 holding.
46 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.